All In Biotech

Drug Trial Radar · NCT04324346

Central Catheters Used for Chemotherapy in Women With Breast Cancer

Evaluation of Central Venous Catheters Used for Chemotherapy in Women With Breast Cancer - An Interdisciplinary Randomized Controlled Study of Complications, Material Wear, Staff- and Patient Perspectives, and Health Economy.

Last checked: Nov 19, 2026Latest source record: Mar 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

Apr 1, 2016

Primary completion

Feb 1, 2021

Study completion Feb 1, 2021

Sponsor

Lead sponsor
Swedish Red Cross University CollegeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Karolinska Institutet; KTH Royal Institute of Technology; Karolinska University Hospital; Stockholm South General Hospital; Norwegian University of Science and Technology
First posted
Mar 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall aim of this study is to evaluate two different central venous lines, PICC-lines (PICC) and subcutaneous venous access ports (SVAP) used for chemotherapy in women with breast cancer. The study will compare complications, material wear of the catheters used, patients'- and health care professionals' experiences, and costs. The study will give knowledge about which central venous access that is the most advantageous regarding adjuvant chemotherapy for women with breast cancer in the aspects of safety, quality of care, and quality of life.

Conditions

  • Catheter Related Complications

Interventions

  • FEC75 (or EC90) x 6Drug

    Type of Chemotherapy

  • FEC100 + Taxotere (EC90 + Taxotere) 3+3Drug

    Type of Chemotherapy

  • PaclitaxelDrug

    Type of Chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ComplicationsTime frame: Through study completion up to 18 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Onkologiska kliniken, Karolinska University Hospital, Danderyd Hospital

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.